MOVE logo

Medacta Group SA Stock Price

SWX:MOVE Community·CHF 2.9b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 2 Fair Values set on narratives written by author
Create a narrative

MOVE Share Price Performance

CHF 145.00
17.40 (13.64%)
7.6% undervalued intrinsic discount
CHF 156.91
Fair Value
CHF 145.00
17.40 (13.64%)
6.1% undervalued intrinsic discount
CHF 154.42
Fair Value
Price CHF 145.00
AnalystConsensusTarget CHF 154.42

MOVE Community Narratives

AnalystConsensusTarget·Updated
Fair Value CHF 156.91 7.6% undervalued intrinsic discount

New Geographic Regions And Acquisitions Will Expand Medical Reach

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative

Recent MOVE News & Updates

Investor Optimism Abounds Medacta Group SA (VTX:MOVE) But Growth Is Lacking

Oct 01
Investor Optimism Abounds Medacta Group SA (VTX:MOVE) But Growth Is Lacking

Medacta Group's (VTX:MOVE) Solid Profits Have Weak Fundamentals

Sep 13
Medacta Group's (VTX:MOVE) Solid Profits Have Weak Fundamentals

Should You Investigate Medacta Group SA (VTX:MOVE) At CHF150?

Sep 12
Should You Investigate Medacta Group SA (VTX:MOVE) At CHF150?

Estimating The Fair Value Of Medacta Group SA (VTX:MOVE)

Aug 29
Estimating The Fair Value Of Medacta Group SA (VTX:MOVE)

Medacta Group (VTX:MOVE) Has Some Way To Go To Become A Multi-Bagger

Aug 01
Medacta Group (VTX:MOVE) Has Some Way To Go To Become A Multi-Bagger

Do Medacta Group's (VTX:MOVE) Earnings Warrant Your Attention?

Jun 24
Do Medacta Group's (VTX:MOVE) Earnings Warrant Your Attention?

What Does Medacta Group SA's (VTX:MOVE) Share Price Indicate?

May 24
What Does Medacta Group SA's (VTX:MOVE) Share Price Indicate?

Market Participants Recognise Medacta Group SA's (VTX:MOVE) Earnings Pushing Shares 26% Higher

May 10
Market Participants Recognise Medacta Group SA's (VTX:MOVE) Earnings Pushing Shares 26% Higher

Medacta Group SA's (VTX:MOVE) CEO Compensation Looks Acceptable To Us And Here's Why

May 01
Medacta Group SA's (VTX:MOVE) CEO Compensation Looks Acceptable To Us And Here's Why

Here's Why Medacta Group (VTX:MOVE) Can Manage Its Debt Responsibly

Apr 24
Here's Why Medacta Group (VTX:MOVE) Can Manage Its Debt Responsibly

Return Trends At Medacta Group (VTX:MOVE) Aren't Appealing

Apr 10
Return Trends At Medacta Group (VTX:MOVE) Aren't Appealing

Medacta Group SA Key Details

€646.1m

Revenue

€209.2m

Cost of Revenue

€436.8m

Gross Profit

€341.9m

Other Expenses

€94.9m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
4.76
Gross Margin
67.61%
Net Profit Margin
14.69%
Debt/Equity Ratio
48.0%

Medacta Group SA Competitors

 
 
 
 
 
 
 
 
 
 
 
 
View more competitors

Snowflake Analysis

Outstanding track record with excellent balance sheet.

1 Risk
2 Rewards
View Full Analysis

About MOVE

Founded
1958
Employees
2041
CEO
Francesco Siccardi
WebsiteView website
www.medacta.com

Medacta Group SA develops, manufactures, and distributes orthopedic and neurosurgical medical devices Latin America, North America, the Asia-Pacific, and Middle East and Africa. It offers personalized 3D planning tools for use in hip, knee, shoulder, joint replacement, sports medicine, and spine surgery. Medacta Group SA was founded in 1958 and is headquartered in Castel San Pietro, Switzerland.

Market Insight

Header cover image

✨Rare Earths: Tiny Market, Outsized Influence

Richard Bowman avatarRichard Bowman
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
Last Week
⚡ Utilities: Defensive Dividends Meet the AI Power Surge

⚡ Utilities: Defensive Dividends Meet the AI Power Surge

Swiss Market Performance

  • 7 Days: 4.0%
  • 3 Months: 3.4%
  • 1 Year: 3.0%
  • Year to Date: 5.8%
The market is up 4.0% in the last 7 days, led by the Healthcare and all sectors gaining ground. The market has been flat overall in the last year. Looking forward, earnings are forecast to grow by 11% annually. Market details ›